Calcium gluconate 600mg tablets
Requires a prescription from a doctor or prescriber
Calcium gluconate is used as mineral supplement and medication when there is insufficient calcium in the diet.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Calcium gluconate
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
3 branded products available
WHO defined daily dose (DDD)
3 gram
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary BNF/ATC mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(2)
Patiromer for treating hyperkalaemia (TA623)
Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate (ESUOM4)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 8 · Randomised trials: 9 · 1973–2026
Showing the 50 most relevant studies, sorted by most relevant.
Franz Sesti, Tiziana Feola, Pasquale Dolce, et al.
European Thyroid Journal, 2025
Lotfalizadeh M, Khadem N, Sadeghi T, et al.
2024
- Ovarian Hyperstimulation Syndrome
- Calcium Gluconate
- Cabergoline
Abirami TL, Rudingwa P, Jha AK, et al.
2025
- Uterine Inertia
- Calcium Gluconate
- Anesthesia, Spinal
Gkanis V, Nastos K, Ntalaperas K, et al.
2026
- Hypoparathyroidism
- Postoperative Complications
- Calcium
Anil V. Ankola, Vinuta Hampiholi, Ram Surath Kumar, et al.
Frontiers in Dental Medicine, 2026
Abirami TL, Rudingwa P, Jha AK, et al.
2026
Khoo KS, Yeo A, Mirzan Asfian MRB, et al.
2024
Emanuel Manzurola, Alexander Apelblat
The Journal of Chemical Thermodynamics, 2002
Pilar Hernández‐Muñoz, Eva Almenar, Valeria Del Valle, et al.
Food Chemistry, 2008
Pilar Hernández‐Muñoz, Eva Almenar, M.J. Ocio, et al.
Postharvest Biology and Technology, 2006
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
Not available
Mechanism
Calcium is essential for the functional integrity of the nervous, muscular, and skeletal systems.
Food interactions
2 warnings
Human targets
None mapped
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
Protein binding
45%
Volume of distribution
Metabolism
Elimination
20%
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Calcium Gluconate Injection, USP is a sterile, nonpyrogenic supersaturated solution of calcium gluconate for intravenous use only. Each mL contains: Calcium gluconate 94 mg; calcium saccharate (tetrahydrate) 4.5 mg; water for injection q.s. Hydrochloric acid and/or sodium hydroxide may have been added for pH adjustment (6.0 to 8.2). Calcium saccharate provides 6% of the total calcium and stabilizes the supersaturated solution of calcium gluconate.
Each 10 mL of the injection provides 93 mg elemental calcium (Ca++) equivalent to 1 g of calcium gluconate.
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 230 interactions
Infants : TDLo ( Intramuscular ) : 143 mg/kg ; Effects - Dermatits
Mouse: LD50 ( intravenous ) : 950mg/kg
Mouse : LDLo (Oral ) : 10gm/kg
How the body processes this drug — absorption, distribution, metabolism, and elimination
ATC B05XA19
ATC A12AA03
ATC D11AX03
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Calcium gluconate
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
Linked open data from Wikidata (Q413739), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication.